Section 845 IAC 2-1-2 - DefinitionsAuthority: IC 25-22.5-13-3
Affected: IC 25-1-9; IC 25-29; IC 35-48-1-9
Sec. 2.
(a) The definitions in this section apply throughout this rule.(b) "Abuse deterrent formulation" means an opioid formulation that has properties shown to meaningfully deter the intentional, nontherapeutic use, even once, to achieve a desirable psychological or physiological effect, even if such formulation does not fully prevent such intentional, nontherapeutic uses.(c) "Chronic pain" means a state in which pain persists beyond the usual course of an acute disease or healing of an injury, or that may or may not be associated with an acute or chronic pathologic process that causes continuous or intermittent pain over months or years.(d) "Controlled substances" has the meaning set forth in IC 35-48-1-9.(e) "Morphine equivalent dose" means a conversion of various opioids to a standardized dose of morphine by the use of accepted conversion tables.(f) "Opioid" means any of various narcotics containing opium or one (1) or more of its natural or synthetic derivatives. However, if such a narcotic is not a controlled substance, it shall not be an opioid for the purposes of this rule.(g) "Outset of an opioid treatment plan" means that a patient has been prescribed opioids as described in section 3(c) of this rule, and, therefore, the provisions stated in section 3(a) of this rule become applicable to that patient.(h) "Terminal" means a condition caused by injury, disease, or illness from which, to a reasonable degree of medical certainty:(1) there can be no recovery; and(2) progression to death can be anticipated as an eventual consequence of that condition.Board of Podiatric Medicine; 845 IAC 2-1-2; filed 7/15/2016, 10:27 a.m.: 20160810-IR-845150416FRAReadopted filed 11/22/2022, 12:26 p.m.: 20221221-IR-845220256RFAReadopted filed 2/20/2024, 9:20 a.m.: 20240320-IR-845230775RFA